Bi-213-anti-EGFR-MAb therapy of recurrent bladder cancer – a pilot study

Following transurethral resection of non-muscle-invasive bladder cancer (carcinoma in situ) and subsequent chemotherapy and treatment with Bacillus Calmette–Guérin (BCG), up to 40% of patients relapse within 5 years and need complete bladder excision. Therefore, new therapeutic strategies to combat tumor recurrence are needed. Because treatment of mice bearing intravesical human bladder cancer xenografts with Bi-213-anti-EGFR-MAb turned out highly efficient, the aim of this pilot study was to evaluate feasibility, safety and therapeutic efficacy of the α-emitter radioimmunoconjugate in recurrent bladder cancer patients.

SCHEIDHAUER Klemens;  SEIDL C.;  BRUCHERTSEIFER Frank;  APOSTOLIDIS Christos;  AUTENRIETH M.;  KURTZ F;  HORN Thomas;  SCHWAIGER M.;  GSCHWEND J.E.;  D’ALESSANDRIA Calo;  PFOB C;  SENEKOWITSCH-SCHMIDTKE R.;  MORGENSTERN Alfred; 

2017-10-25

SPRINGER

JRC106724

1619-7070,   

https://link.springer.com/journal/259/44/2/suppl/page/1,    https://publications.jrc.ec.europa.eu/repository/handle/JRC106724,